F
Fabien Zoulim
Researcher at French Institute of Health and Medical Research
Publications - 716
Citations - 40988
Fabien Zoulim is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 96, co-authored 641 publications receiving 35807 citations. Previous affiliations of Fabien Zoulim include Hotel Dieu Hospital & University of Orléans.
Papers
More filters
Journal ArticleDOI
Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles.
Olivier Hantz,Christelle Borel,C. Trabaud,Fabien Zoulim,Jean Dessolin,Michel Camplo,Patrick Vlieghe,M. Bouygues,Christian Trepo,Jean Louis Kraus +9 more
TL;DR: Three of the four tested compounds were able to selectively inhibit DHBV replication by acting at an early step of the hepadnavirus infection but were associated with significant toxicity.
Journal ArticleDOI
Non-F HBV/HDV-3 coinfection is associated with severe liver disease in Western Brazilian Amazon.
Edinete Melo da Silva,Alan Kay,Cirley Lobato,Richard Muwonge,Fabien Zoulim,Carlos Brites,Raymundo Paraná,Christian Trepo +7 more
TL;DR: HBV/HDV coinfection was associated with male sex, age above 30 years, severe liver disease, and increased alanine aminotransferase levels, in Rio Branco, Brazil.
Journal ArticleDOI
Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system.
Vanessa Escuret,Amaury Martin,David Durantel,Romain Parent,Olivier Hantz,Christian Trepo,Thierry Menguy,Emmanuel Bottius,Jerome Dardy,Jean Maral,Jean Louis Escary,Fabien Zoulim +11 more
TL;DR: It is demonstrated that, in the BM4-5 cell line harboring an HCV subgenomic replicon, a novel and naturally occurring human IFN-α17 variant, GEA007.1, which was discovered by using an original population genetics-based drug discovery approach, inhibits HCV genotype 1 RNA replication more efficiently than does IFn-α2b.
Journal ArticleDOI
A cyclic PNA-based compound targeting domain IV of HCV IRES RNA inhibits in vitro IRES-dependent translation.
Sergio A. Caldarelli,Mohamed Mehiri,Audrey Di Giorgio,Amaury Martin,Olivier Hantz,Fabien Zoulim,Raphaël Terreux,Roger Condom,Nadia Patino +8 more
TL;DR: Although preliminary biological assays have revealed the ability of 1 to inhibit in vitro the HCV IRES-dependent translation in a dose-dependent manner, the linear analog has shown a slightly higher activity.
Journal ArticleDOI
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study
Patrick Miailhes,Marianne Maynard-Muet,Fanny Lebossé,Fabrice Carrat,Cécile Bouix,Caroline Lascoux-Combe,Philippe Sogni,David Rey,Yoann Barthe,Stanislas Pol,Patrice Cacoub,Fabien Zoulim,Lionel Piroth +12 more
TL;DR: 48-week PegIFN additional therapy to cART including TDF did not significantly increase the HBe seroconversion rate, despite an HBeAg loss in 20% of the patients, and HBe and HBs kinetics may nevertheless be of help in tailoring and optimising this strategy.